13.02.2024 - BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) - Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel .
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A 6 IPO Week seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
By Josh Beckerman Telomir Pharmaceuticals shares were down 18% to $5.71 Friday in their Nasdaq debut. The company said Thursday that its initial public.
Metagenomi finds novel gene-editing tools by mining microbial samples from around the world. Already partnered with Moderna and Ionis Pharmaceuticals, the company said its IPO cash will support ongoing preclinical research.
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.